Since its establishment in 1994, Shenzhen Xingyin Pharmaceutical Co., Ltd. (hereinafter referred to as "Xingyin Pharmaceutical") has focused on the development of the pharmaceutical industry and has gradually grown into a comprehensive pharmaceutical group enterprise integrating science, industry and trade. Over the past 20 years, Xingyin Pharmaceutical has established 10 pharmaceutical subsidiaries in Shenzhen, Nanjing, Hubei and other places, and has established prescriptions nationwide: 4 major regions, 8 provinces and regions, and 67 offices; retail: 5 A professional academic marketing team has been built in the region and 25 sales areas. So far, Xingyin Pharmaceutical has a complete pharmaceutical industry chain and is an excellent pharmaceutical company with strong independent innovation capabilities and high sustainable development capabilities in China.

Since its establishment, Xingyin Pharmaceutical has insisted on contributing high-quality products, serving the people and benefiting the society. In the early 1990s, Xingyin Pharmaceutical introduced the German pure plant medicine Maizhiling tablets. Its products independently developed and produced Xingrui, Gegen Decoction, compound codeine phosphate oral solution and other products, which were widely used in major domestic hospitals. The clinical department has received unanimous praise from clinical experts and the majority of patients.

In 2002, Xingyin Pharmaceutical built a large modern pharmaceutical production base covering an area of ​​250 acres in Lishui Economic Development Zone, Jiangsu Province, and was engaged in the production of various dosage form drugs. In order to achieve continuous innovation in drug research and development and production technology, in 2010, Xingyin Pharmaceutical Investment Holds Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. In February of the same year, Jianyuan Pharmaceutical officially established a R&D laboratory in the biological incubator of Shenzhen High-tech Zone and started the construction of Nanjing Lishui Raw Materials Production Center. In 2013, Jianyuan Pharmaceutical settled in the "Shenzhen National Bioindustry Base" in Pingshan New District and built three new drug preparation production lines and a 5,000 square meter R&D center laboratory that meets the national new drug R&D standards.

In 2015, Xingyin Investment Group signed a contract with 660 mu of land in the Xian'an Economic Development Zone, Hubei to build a new bio-raw drug production base, headquarters meeting, training, reception, information center and R&D center. After production, Hubei Jianxiang will be Become a large-scale production base for polypeptide raw materials in China and even Asia. At present, Xingyin Pharmaceutical has nearly 100 invention patents and product design patents, more than 30 new drugs of various types under development, and no less than 4 new biological agents have entered the approval sequence every year. As a high-tech enterprise, Xingyin Pharmaceutical makes great efforts in the field of pharmaceutical research and development every year, striving to accelerate the development of innovative drugs and become stronger and bigger in the pharmaceutical market.